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PURPOSE. We sought to determine the role of glycogen synthase kinase-3β (GSK-3β) in
the pathogenesis of Graves’ orbitopathy(GO).
METHODS. Expression of the GSK-3β gene in whole orbital tissue explants was compared
between GO and non-GO donors using quantitative real-time PCR (RT-PCR). The expres-
sion of proinflammatory molecules in the presence of the GSK-3β inhibitor CHIR 99021
was analyzed using RT-PCR, western blot, and ELISA. Adipogenic differentiation was
identified using Oil Red O staining, and the levels of peroxisome proliferator activator
gamma (PPARγ ) and CCAAT-enhancer-binding proteins (C/EBPs) α and β were deter-
mined by western blot.
RESULTS. The expression of GSK-3β was significantly higher in GO tissues than in control
tissues. The addition of CHIR 99021 led to a decrease in the active form of the kinase
in which the Y216 residue is phosphorylated. When GO and non-GO fibroblasts were
stimulated with IL-1β or TNF-α, IL-6, IL-8, intercellular adhesion molecule-1 (ICAM-1),
cyclooxygenase-1 (COX-1), and monocyte chemoattractant protein 1 (MCP-1) showed
increased production, which was blunted when CHIR 99021 was added. The activation of
Akt, PI3K, nuclear factor (NF)-κB, Erk, Jnk, and p38 kinase by IL-1β and TNF-α was dimin-
ished with CHIR 99021 in GO cells. A decrease in lipid droplets and expression of PPARγ
and c/EBPα and -β was noted in fibroblasts treated with CHIR 99021 during adipocyte
differentiation. The inhibition of Wnt and β-catenin in adipogenesis was reversed by
CHIR 99021.
CONCLUSIONS. GSK-3β plays a significant role in GO pathogenesis. The inhibition of the
kinase attenuated the proinflammatory cytokines production and fibroblast differentia-
tion into adipocytes. GSK-3β may be a potential target for anti-inflammatory and anti-
adipogenic treatment of GO.
Keywords: Graves’ orbitopathy, inflammation, adipogenesis, glycogen synthase kinase-
3β, orbital fibroblast
Graves’ orbitopathy (GO) is characterized by extensiveremodeling of soft tissues in the orbit.1 Many stud-
ies have attempted to elucidate its pathogenesis. Although
the importance of different cell types has been debated,
orbital fibroblasts in particular have recently gained consid-
erable attention as the main agent of the disease process.2,3
In response to the inflammatory cells that infiltrate the
space, fibroblasts proliferate and secrete proinflammatory
cytokines, actively inciting and perpetuating inflamma-
tion.4 During the process, they may also differentiate into
adipocytes and myofibroblasts and secrete extracellular
matrix components, including hydrophilic glycosaminogly-
cans.5 Ultimately, the resultant increase in soft tissue volume
within the confined bony orbit clinically leads to proptosis,
compressive optic neuropathy, and periorbital edema.
Recent advances in genomic studies have allowed discov-
eries of molecular mechanisms driving the pathogenesis of
GO. The nuclear factor kappa-light-chain-enhancer of acti-
vated B cells (NF-κB) pathway, Wnt/β-catenin pathway, and
phosphoinositide 3-kinase (PI3K)/Akt pathways are among
a number of signaling pathways that have been found to
play cardinal roles.2,6,7 At the intersection of these pathways
lies one molecule: glycogen synthase kinase-3beta (GSK-
3β). However, other than a small number of studies that
have examined its role in inflammation in adipose tissues,8,9
no studies to date have conducted an extensive analysis of
its function with respect to the pathogenesis of GO. In this
regard, the present study was designed to characterize the
role of GSK-3β in GO fibroblasts in vitro. We investigated
the expression of GSK-3β in GO fibroblasts and identified
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its role in inflammation and adipocyte differentiation of
fibroblasts obtained from the orbits of patients with GO by
employing the GSK-3β-specific inhibitor CHIR 99021.
METHODS
Reagents
The antibodies were purchased from Cell Signaling Tech-
nology (Beverly, MA, USA), BD Biosciences (San Jose, CA,
USA), Santa Cruz Biotechnology (Santa Cruz, CA, USA),
Novus Biologicals (Centennial, CO, USA), and Abcam
(Cambridge, UK). The antibodies used are listed in detail
in Supplementary Table S1. CHIR 99021 was a product
of Tocris Bioscience (Minneapolis, MN, USA). Recom-
binant human IL-1β was a product from R&D Systems
(Minneapolis, MN, USA). The enzyme-linked immunosor-
bent assay (ELISA) kits for IL-6 and IL-8 were purchased
from R&D Systems (Minneapolis); for MCP-1, from R&D
Systems (Abingdon, UK); and for ICAM-1, from Abcam. The
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium (MTT) assay and Oil
Red O were purchased from Sigma-Aldrich (St. Louis,
MO, USA). Dulbecco’s modified Eagle’s medium (DMEM),
fetal bovine serum (FBS), penicillin, and gentamicin were
purchased from Hyclone Laboratories, Inc. (Logan, UT,
USA).
Subjects and Preparation of Tissues and Cells
The GO patient cohort was comprised of six men and
nine women (mean age, 43.9 ± 5.7 years). Their orbital
adipose/connective tissues were obtained during orbital
decompression from tissues normally discarded. All GO
patients were in a stable euthyroid state for a minimum
of 3 months with clinical activity scores less than 4 and
were free of steroid or radiotherapy treatment for at least
3 months prior to surgery. The control patient popula-
tion was comprised of three men and six women (mean
age, 42.2 ± 6.7 years) undergoing either evisceration or
orbital wall fracture repair. The control patients had no
known history or clinical evidence of any thyroid disease. All
patients provided written informed consent for the surgical
procedure and study participation. The study protocol was
reviewed and approved by the Institutional Review Board
of Severance Hospital, and the study adhered to the tenets
of Declaration of Helsinki. The clinical characteristics of the
patient population of this study are detailed in Supplemen-
tary Table S2.
The isolation of the orbital fibroblasts followed a standard
protocol in published literature.10 In short, the harvested
tissues were minced and placed in DMEM/F12 (1:1 ratio)
medium containing 20% FBS, penicillin (100 U/mL), and
gentamycin (20 μg/mL). Following incubation, tissues were
maintained in solution containing DMEM, antibiotics, and
10% FBS. When the growth of the fibroblasts had been
confirmed, the cells were treated with trypsin/EDTA and
passaged in monolayers. The cell strains were stored in
liquid nitrogen and only those between the third and fifth
passages were used for experiments.
Cell Viability Assay
The MTT assay was employed to test cell viability. Following
the manufacturer’s protocol (Sigma-Aldrich), orbital fibrob-
lasts isolated from GO patients and healthy non-GO donors
were seeded into 24-well culture plates (1 × 105 cells/well)
and treated with dimethylsulfoxide (DMSO; vehicle control)
and different concentrations of CHIR 99021 (1, 5, 10, and
20 μM) for 18, 24, 48, and 72 hours. Thereafter, cells were
washed and incubated in 5-mg/mL MTT solution for 3 hours
at 37°C. Ice-cold isopropanol was applied for solubilization,
and the absorbance of the converted dye was measured with
a microplate reader (EL 340 Microplate Bio Kinetics Reader;
Bio-Tek Instruments, Winooski, VT, USA) at 560 nm, with
background subtraction at 630 nm.
Quantitative Real-Time PCR
The RNA was extracted from cells with Invitrogen TriZol
(Thermo Fisher Scientific, Waltham, MA, USA). Out of the
extract, 1 μg was reverse-transcribed into cDNA (Qiagen,
Hilden, Germany) and amplified with SYBR Green Real-
Time PCR Master Mix in a StepOne Plus real-time PCR
thermocycler (Applied Biosystems, Carlsbad, CA, USA). The
sequence of primers is listed in detail in Supplementary
Table S3. The PCR results for each type of mRNA were
normalized to the level of glyceraldehyde-3-phosphate dehy-
drogenase and expressed as fold change in the Ct value
relative to the control group in accordance with the 2–Ct
method.11
Western Blot Assay
Orbital fibroblasts subjected to different study conditions
were washed with PBS and then lysed with cell lysis buffer
on ice.12 The lysates were centrifuged, and the supernatants
were resolved in 10% SDS-polyacrylamide gel electrophore-
sis (SDS-PAGE), followed by transfer onto polyvinylidene
fluoride membranes (Immobilon; Millipore Corp., Billerica,
MA, USA). The membranes were then probed with primary
antibodies in tris-buffered saline and Tween 20 along with
1% BSA and 0.01% sodium azide. Then, the membranes were
probed with horseradish peroxidase-conjugated secondary
antibody with chemiluminescence (Cell Signaling Technol-
ogy), using 5% skimmilk as the blocking solution. The bands
were detected on x-ray films (Agfa, Mortsel, Belgium), and
their intensities were quantified and normalized to that of
the β-actin in the same sample.
ELISA
According to the manufacturer’s instructions, supernatants
were collected from cell cultures and diluted, and assays
were performed to quantify the levels of IL-6, IL-8, ICAM-
1, and MCP-1. The absorbance was measured at 405 nm to
determine the percentage of binding for each sample, and
a standard binding curve was then drawn to determine the
concentrations. The average value of three repeated assays
was used for statistical analyses.
Adipogenesis
Fibroblasts were induced to differentiate into adipocytes
following a previously published protocol.13,14 Briefly, cells
were cultured in serum-free DMEM supplemented with
T3, insulin (Boehringer-Mannheim, Mannheim, Germany),
carbaprostaglandin (cPGI2; Calbiochem, La Jolla, CA,
USA), and dexamethasone, along with a peroxisome
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FIGURE 1. Expression of GSK-3β mRNA in GO tissues in compar-
ison to non-GO tissues. RNA was extracted from GO (n = 15) and
non-GO (n = 9) orbital tissues, and the GSK-3β transcript levels
were compared between GO and non-GO tissues using real-time
PCR. A single dot represents the value obtained from the experi-
ment on a single donor (*P < 0.05 vs. non-GO tissues).
proliferator activator gamma (PPARγ ) agonist, rosiglitazone
(10 μM; Cayman Chemical, Ann Arbor, MI, USA) for 10 days.
Oil Red O Staining
A working solution was prepared by diluting 6 mL of a
stock solution (0.5% Oil Red O in isopropanol) with 4 mL
of distilled water. The cells were fixed with 3.7% formalin
at 4°C for 15 minutes before being washed with PBS and
mixed with the solution for 1 hour at room temperature.
The cell–solution mixture was visualized under a light micro-
scope (Olympus BX60; Olympus Corp., Melville, NY, USA).
The Oil Red O staining protocol has been described in detail
by Green and Kehinde.15
Statistical Analysis
All experiments were performed at least three times with
samples from each patient, and the results were expressed
as mean ± SD. Independent t-tests and ANOVA were
employed for comparisons between GO and non-GO tissue
explants and also among DMSO-treated, stimulant-treated,
and stimulant- and inhibitor-treated cell groups. The Bonfer-
roni test was performed as a post hoc test. SPSS Statistics 20
(IBM, Armonk, NY, USA) was used. P < 0.05 was considered
statistically significant.
RESULTS
GO Tissues Show Increased Expression of GSK-3β
RNA was extracted from whole orbital tissue explants of 15
GO and nine non-GO subjects, and GSK-3β transcript levels
were compared between GO and non-GO using real-time
PCR (RT-PCR (Fig. 1). The RT-PCR results showed that the
expression of GSK-3β mRNA was greater in GO tissues (n
= 15) than in the control orbital tissues (n = 9).
CHIR 99021 Inhibits GSK-3β in GO Fibroblasts
An MTT assay was conducted in order to identify the non-
toxic concentrations of the GSK-3β inhibitor CHIR 99021
for orbital fibroblasts (Fig. 2). The results revealed that more
than 95% of both GO and non-GO fibroblasts were viable
when CHIR 99021 was applied in concentrations up to 20
μM for at least 72 hours. Based on these results, when analyz-
ing the effect of CHIR 99021, CHIR 99021 was applied in
concentrations below 20 μM for less than 72 hours for the
remainder of the study.
When GO fibroblasts were challenged with IL-1β and
TNF-α, increased production of both active (phosphoryla-
tion of Y216 residue) and inactive (phosphorylation of S9
residue)16,17 forms of GSK-3β were observed in western
blot (Fig. 3A, Supplementary Fig. S2). The addition of CHIR
99021 to the medium significantly inhibited the expression
of both active and inactive forms of the kinase while the
total amount of GSK-3β remained unchanged. When GO
fibroblasts were treated with CHIR 99021, the cell lysates of
fibroblasts collected at different time points showed a grad-
ual decrease in production of both the active and inactive
forms GSK-3β (Fig. 3B). The decrease was especially promi-
nent for the active form (Y216).
GSK-3β Mediates Elevated Expression of
Proinflammatory Cytokines in GO
The GO and non-GO fibroblasts were treated with DMSO
for 3 hours, 10 ng/mL of IL-1β for 3 hours, or IL-1β for
FIGURE 2. Effect of CHIR 99021 on the viability of orbital fibroblasts. Orbital fibroblasts of GO and non-GO patients were seeded in 24-well
culture plates, 1 × 105 cells per well. Various concentrations (0–20 μM) of CHIR 99021 were applied to wells for 18, 24, 48, and 72 hours,
and an MTT assay was conducted to test cell viability. Results are expressed as a percentage of untreated control and are presented as mean
± SD. Assays were performed at least three times in triplicate. Differences between treated and untreated cells are indicated (*P < 0.05).
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FIGURE 3. CHIR 99021 suppresses GSK-3β. (A) Confluent orbital fibroblasts obtained from GO patients (n = 3) were treated with DMSO and
10 ng/mL of IL-1β or TNF-α for 15 minutes with or without pretreatment with 10-μM CHIR 99021 for 48 hours. Western blot analyses were
performed to investigate the levels of inactive GSK-3β (p-GSK-3β [S9]), active GSK-3β (p-GSK-3β [Y216]), and total GSK-3β. Although the
treatment with proinflammatory cytokines led to a significant increase in the levels of inactive GSK-3β (p-GSK-3β [S9]) and active GSK-3β
(p-GSK-3β [Y216]), pretreatment with CHIR 99021 significantly suppressed the increase. (B) Confluent orbital fibroblasts obtained from GO
patients (n = 3) were treated with CHIR 99021 for increasing lengths of time (0–48 hours) without stimulant. Increasing durations of CHIR
99021 treatment resulted in decreased p-GSK-3β (Y216) levels. Data in the columns indicate the mean density ratio ± SD, normalized to the
level of β-actin in the same sample. Representative gel images are also shown. Differences between treated and untreated cells are indicated
(*P < 0.05). For full-length gel images, see Supplementary Figure S2.
3 hours following pretreatment with the GSK-3β inhibitor
CHIR 99021 for 1 hour (Fig. 4A). In comparison to the
DMSO-treated cells, IL-1β-challenged fibroblasts showed
an increased expression of mRNA of the proinflamma-
tory cytokines IL-6, IL-8, ICAM-1, cyclooxygenase-2 (COX-2),
and MCP-1. When CHIR 99021 was added to the medium,
the elevated mRNA expression of all the cytokines was
blunted in GO and control fibroblasts. The investigation was
repeated with the stimulant switched from IL-1β to TNF-
α (Fig. 4B). Likewise, the RT-PCR results showed that the
stimulation with TNF-α led the GO and control fibroblasts
to increase mRNA expression of all of the proinflammatory
cytokines, which was then suppressed when CHIR 99021
was added. The western blot analyses with the same condi-
tion echoed the results of RT-PCR (Fig. 5). The increased
production of the five cytokines by GO and control fibrob-
lasts in response to challenge with IL-1β or with 10-ng/mL
TNF-α for 16 hours was blunted with the addition of CHIR
99021 (Fig. 5, Supplementary Fig. S3). The effect of CHIR
99021 on the release of proinflammatory cytokines was
analyzed with ELISA in both GO and non-GO cells (Supple-
mentary Fig. S1). The increased level of secretory proinflam-
matory cytokines in response to IL-1β and TNF-α stimulation
was significantly suppressed by the addition of CHIR 99021
in both GO and non-GO fibroblasts.
Adipocyte Differentiation in GO is Dependent on
the Activity of GSK-3β
When confluent orbital fibroblasts taken from GO patients
were treated with the adipogenic medium for 10 days
to induce their differentiation into adipocytes, the fibrob-
lasts lost their stellate appearance and morphologically
conformed into a spherical shape with intracellular lipid
droplets (Fig. 6A). When the GSK-3β inhibitor CHIR 99021
was added to the medium in increasing concentrations,
adipogenesis identified with Oil Red O staining decreased
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FIGURE 4. The effect of GSK-3β inhibitor on the transcription of proinflammatory cytokines in GO fibroblasts in comparison to control
fibroblasts. (A) Cells obtained from GO patients (n = 3) and control patients (n = 3) were treated with DMSO for 3 hours, as well as 10
ng/mL of IL-1β for 3 hours and IL-1β for 3 hours after pretreatment with GSK-3β inhibitor (10-μM CHIR 99021) for 1 hour. The RNA extracted
from each sample was reverse-transcribed by real-time PCR and quantified. The results showed elevated levels of IL-6, IL-8, ICAM-1, COX-2,
and MCP-1 in response to IL-1β treatment, which was significantly suppressed by the addition of CHIR 99021. (B) The same experiment
was repeated with TNF-α. The results are shown as mean ± SD fold expression of three separate experiments (*P < 0.05 vs. IL-1β- or
TNF-α-stimulated cells).
in a dose-dependent manner. Quantification of the opti-
cal density of Oil Red O staining at 490 nm confirmed
the histochemical results (Fig. 6B). Increasing concentra-
tions of CHIR 99021 led to dose-dependent decreases in
the adipogenic transcription factors PPARγ and CCAAT-
enhancer-binding protein (C/EBP) α and β (Fig. 6C, Supple-
mentary Fig. S4). Markers of mature adipocytes, fatty acid-
binding protein 4 (FABP4) and Acrp30, which were detected
on day 10 of adipogenic differentiation in control-treated
fibroblasts, were significantly suppressed upon CHIR 99021
treatment. Further, the Wnt/β-catenin signaling pathway was
assessed. The inactive and active forms of GSK-3β that
showed an increase during adipogenesis decreased follow-
ing the treatment with CHIR 99021. The β-catenin levels that
decreased during adipogenesis significantly increased in a
dose-dependent manner with CHIR 99021 treatment, and
cyclin D1 that increased during adipogenesis significantly
decreased in a dose-dependent manner with CHIR treat-
ment. The results suggest that GSK-3β plays a role in induc-
ing adipogenic differentiation of fibroblasts in GO through
the canonical Wnt/β-catenin signaling pathway.
Inhibition of GSK-3β Decreases Activation of
Proinflammatory Signaling Molecules
In order to identify signaling pathways affected by the
regulation of the kinase, multiple transcription factors were
assayed. Figure 7 illustrates the results of the western blot
analyses. In comparison to the DMSO-treated fibroblasts, IL-
1β-treated GO fibroblasts (10 ng/mL of IL-1β for 15 minutes)
showed increased levels of phosphorylated forms of proin-
flammatory signaling molecules, including Akt, PI3K, NF-
κB, extracellular signal-regulated kinase (ERK), p38 and c-
Jun NH(2)-terminal kinase (JNK). When CHIR 99021 was
applied for 48 hours prior to the challenge with IL-1β,
the level of phosphorylated forms relative to the total
amount of the same protein significantly decreased for
all eight of the transcription factors tested. The response
of the GO fibroblasts to incubation with 10-ng/mL TNF-
α and CHIR 99021 demonstrated a similar trend (Fig. 7A).
In control fibroblasts, treatment with CHIR 99021 led to
significant reduction in only Akt, ERK, and JNK (Fig. 7B).
In response to 10-ng/mL TNF-α, the reduction by CHIR
99021 was significant only for Akt, PI3K, p38, and JNK
(Supplementary Fig. S5).
DISCUSSION
In this study, we examined the role of GSK-3β in the
pathogenesis of GO. The challenge with proinflammatory
cytokines led to an increase in both active and inac-
tive forms of GSK-3β. The GSK-3β inhibitor CHIR 99021
significantly decreased proinflammatory cytokine produc-
tion, adipogenic transcription factors, and adipocyte forma-
tion. In response to inflammatory and adipogenic stimulants
applied to primary culture cells to mimic in vivo conditions,
the rise in secretory cytokines and transcription factors was
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FIGURE 5. The effect of GSK-3β inhibitor on the protein levels of proinflammatory cytokines in GO and control fibroblasts. (A) Orbital
fibroblasts obtained from GO patients (n = 3) and control non-GO patients (n = 3) were treated with 10-ng/mL IL-1β and 10-ng/mL TNF-α
for 16 hours. The cells were also subjected to pretreatment with 10-μM CHIR 99021 for 48 hours before the challenge with either stimulant.
Western blot analyses were conducted to compare levels of the proinflammatory cytokines IL-6, IL-8, ICAM-1, COX-2, and MCP-1. The
representative gel images are also shown. The molecular weights of the detected bands are marked to the left of the bands (kDa). (B) The
results from GO fibroblasts are presented as the mean density ratio ± SD, normalized to the level of β-actin in the same sample. (C) The
same experiment was repeated in the control fibroblasts, and results are shown as the mean density ratio ± SD fold expression of three
separate experiments, normalized to the level of β-actin in the same sample (*P < 0.05 vs. IL-1β- or TNF-α-stimulated cells). For full-length
gel images, see Supplementary Figure S3.
more prominent in GO fibroblasts in comparison to the non-
GO fibroblasts. Together with the higher mRNA level of GSK-
3β in GO orbital tissues, which most closely resembles the in
vivo conditions, our study demonstrates that GSK-3β plays a
central role in inflammatory reactions and adipocyte differ-
entiation of GO fibroblasts (Fig. 8).
A number of studies have made attempts at clarifying the
importance of GSK-3β in thyroid diseases. For instance, Rao
et al.18 suggested a possible role for GSK-3β in the regu-
lation of thyrocyte proliferation; inhibition of the kinase
with lithium allowed the Wnt/β-catenin signaling pathway to
stimulate the proliferation of thyrocytes. Indeed, the kinase
has been included as an important tumor suppressor in
thyroid carcinogenesis models in several studies.19,20 In the
context of GO, however, studies on the kinase are scarce.
In 2018, Yang et al.21 confirmed that single nucleopeptide
polymorphisms within the genetic sequence of GSK-3β were
associated with 1.4 to 2.7 times greater susceptibility to GO.
In 2015, Shen et al.22 postulated that downregulation of
GSK-3β was the mechanism by which microRNA (miR-224-
5p), when over-expressed, increased the sensitivity of GO to
glucocorticoid therapy. To our knowledge, this study is the
first of its kind to confirm the role of GSK-3β in the patho-
genesis of GO. Our results showed that GSK-3β is expressed
at higher levels in GO tissues compared to the control. More
importantly, the inhibition of this enzyme ameliorated proin-
flammatory and adipogenic reactions of orbital fibroblasts of
GO.
Previous reports have partially discovered the mechanism
of GO at a molecular level. From what has been identi-
fied, orbital fibroblasts are believed to actively interact with
immune cells, secrete proinflammatory cytokines, and main-
tain orbital inflammation in GO.23,24 Evidence shows activa-
tion of the p38, Erk, JNK, and NF-κB pathways for expres-
sion of proinflammatory genes, including ICAM-1, IL-6, IL-
8, and MCP-1.25,26 In accordance with previous studies,27,28
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FIGURE 6. GSK-3β mediates adipogenic differentiation of GO fibroblasts. Orbital fibroblasts from GO (n = 3) patients were cultured in
adipogenic medium to induce differentiation into adipocytes. (A) Oil Red O staining showed that increasing concentrations of CHIR 99021
inhibited adipogenesis in a dose-dependent manner. (B) Measurements of the optical density of cell lysates at 490 nm showed the same
results. Experiments were conducted on three cell strains, and the results are expressed as the mean optical density (%) ± SD (*P < 0.05
vs. untreated controls). (C) Western blot analyses of adipogenic transcription factors PPARγ , C/EBPα, and C/EBPβ showed decreased levels
in response to increasing concentrations of CHIR. The levels of mature adipocyte markers, FABP4 and Acrp30, were significantly reduced
in fibroblasts treated with higher concentrations of CHIR 99021. Increasing concentrations of CHIR led to decreased levels of inactive and
active GSK-3β and increased levels of inactive (np-β-catenin) and total β-catenin. The molecular weights of the detected bands are marked
to the left of the bands (kDa). Data in the columns indicate the mean density ratio ± SD, normalized to the level of β-actin in the same
sample (n = 3), and representative gel images are shown (*P < 0.05 vs. control fibroblasts on day 10 of adipogenesis). For full-length gel
images, see Supplementary Figure S4.
our study showed increased production of proinflamma-
tory cytokines, as well as NF-κB protein, in the IL-1β- and
TNF-α-stimulated GO fibroblasts, which was then curtailed
with the addition of the GSK-3β inhibitor. According to
the literature, GSK-3β is believed to activate NF-κB and
produce a proinflammatory effect.29,30 Some studies suggest
that IκB kinase, IκB, and p65 are substrates of GSK-3β.31
Other studies have associated GSK-3β with cAMP response
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FIGURE 7. The role of GSK-3β in the activation of signaling molecules in response to proinflammatory cytokines treatment. (A) Confluent
orbital fibroblasts obtained from GO patients (n = 3) were treated with DMSO (D), and 10-ng/mL of IL-1β (IL) or TNF-α (TN) for 15 minutes
with or without pretreatment with 10-μM CHIR 99021 (C) for 48 hours. Representative gel images are shown. The molecular weights of the
detected bands are marked to the right of the bands (kDa). Data in the columns indicate the mean density ratio ± SD of the bands obtained
from the GO patients, normalized to the level of β-actin in the same sample. Treatment with IL-1β or TNF-α resulted in a significant increase
in the levels of phosphorylated forms of Akt, PI3K, NF-κB, Erk, p38, and Jnk. Pretreatment with the GSK-3β inhibitor CHIR 99021 blunted
the increases in the transcription factors. (B) The same experiment was repeated with fibroblasts obtained from non-GO patients (n = 3).
Representative gel images are shown, where the molecular weight of each band is marked on the right. The mean density ratios ± SD
from the control fibroblasts were normalized to the level of β-actin in the same sample (*P < 0.05 vs. IL-1β- or TNF-α-stimulated cells). For
full-length gel images, see Supplementary Figure S5.
element-binding protein (CREB); the suppression of GSK-3β
activity is believed to allow CREB to remove the co-activator
CREB-binding protein from NF-κB.31–33 The decreased acti-
vation of NF-κB, PI3K/Akt, and MAPK signaling pathways as
presented in our study may be associated with the ability of
GSK-3β inhibitor to contain inflammation in the confluent
GO fibroblasts.
Current literature on adipogenesis indicates that the
process largely takes place in two phases: the early phase,
in which C/EBPα is expressed immediately following the
exposure to an adipogenic medium to mediate cell prolif-
eration, and the late phase, in which PPARγ and C/EBPβ
are responsible for terminal differentiation of fibroblasts
into adipocytes.34 Recently, a study on murine 3T3-L1
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FIGURE 8. Schematic diagram of the GSK-3β signaling in orbital fibroblasts of Graves’ orbitopathy. GSK-3β mediates proinflammatory
reactions by activating PI3K, MAP kinases (p38, JNK, and ERK), and NF-κB. By inducing nuclear translocation of β-catenin and activating
C/EBPα and β, the kinase also plays a critical role in inducing adipocyte differentiation.
preadipocytes found that both stages are regulated by GSK-
3β.35 The inhibition of GSK-3β decreased the expression
of the transcription factors responsible for the two stages.
These results are in accordance with those of our study.
Increasing concentrations of CHIR 99021, a highly selec-
tive adenosine triphosphate (ATP)-competitive synthetic
inhibitor of GSK-3β,36 led to the loss of adipocyte morphol-
ogy under the microscope. Inhibition of GSK-3β also led to
corresponding decreases in PPARγ , C/EBPα, and C/EBPβ in
our cell populations. GSK-3β appears to achieve this effect,
at least in part, by regulating the expression of Wnt genes.
Among the Wnt subtypes, Wnt4 and Wnt5b are promoters
of adipogenesis and are downregulated upon inhibition of
the enzyme,37 whereas Wnt3a and Wnt10a hinder adipo-
genesis and are upregulated by CHIR 99021 treatment.38,39
Although in our study we did not investigate the expression
of Wnts in detail, GSK-3β inhibition caused upregulation of
Wnt3 and increased nuclear translocation of β-catenin that
culminated in suppression of adipogenesis. In addition to
the canonical Wnt pathway that was examined in our anal-
yses, GSK-3β may also regulate adipogenesis by affect-
ing non-canonical Wnt signaling pathways.35 Studies have
shown in the past that activation of non-canonical Wnt path-
ways by suppression of GSK-3β caused JNK to be phospho-
rylated and curb adipogenesis.40,41 As such, evidence regard-
ing the importance of Wnt signaling pathways in the patho-
genesis of GO is mounting; recently, we found that suppres-
sion of the adipogenesis of GO fibroblasts by curcumin
involved activation of the canonical Wnt signaling pathway,
as well.42
The changes in the phosphorylation of multiple transcrip-
tion factors upon the addition of GSK-3β inhibitor in our GO
fibroblasts indicate that a more complex network of signal-
ing pathways may exist than once believed. Kumar et al.28
discovered that an auto-antibody against thyroid-stimulating
hormone receptor stimulated the PI3K/Akt pathway down-
stream and induced adipogenesis of orbital preadipocytes in
GO. They argued in their study that this pathway triggered
the terminal stages of adipogenesis. Similarly, the present
study showed that GSK-3β inhibition decreased the activa-
tion of PI3K and Akt and attenuated adipogenesis in orbital
fibroblasts also taken from GO patients. Based on the results
of our study, we suspect that GSK-3β may be involved in
the feedback regulation of PI3K/Akt signaling. A number
of studies have presented results that support our view. In
breast cancer cell lines and murine embryonic fibroblasts,
the loss of GSK-3β by genetic deletion has been shown to
cause reduced activation of Akt.43 Additionally, studies in
the past have shown that active GSK-3β regulates the func-
tional antagonist of PI3K, PTEN; it phosphorylates PTEN
at Thr262 at the regulatory C-terminal tail, reducing the
function of the antagonist.44,45 As the mechanism by which
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GSK-3β is regulated remains elusive, further studies are
necessary to identify the interaction of GSK-3β with other
signaling molecules.
Despite the admittedly perplexing role of GSK-3β in a cell
system, multiple studies have repeatedly proven the thera-
peutic benefits of GSK-3β inhibition in a variety of disor-
ders, including neurodegenerative, cognitive, and psycho-
logical diseases.46,47 Lithium reversibly binds the enzyme at
the magnesium binding site or reduces the activity of the
phosphatase that removes a phosphate from the serine 9
residue of the enzyme.48 Another inhibitor, thiadiazolidinone
8, is a non-ATP competitive inhibitor of GSK-3β.49 Apart
from psychiatric diseases, for which the two inhibitors are
already widely in use,50 they have been tried in Alzheimer’s
diseases, bone diseases, and inflammatory diseases with
limited success.51,52 Even though a number of other GSK-3β
inhibitors do exist and have shown promise in many studies,
in the context of thyroid diseases no attempts at targeting
GSK-3β for treatment have been made, to our knowledge.
The results of this study may stimulate future development
of clinical trials aimed at testing the effect of GSK-3β inhibi-
tion on Graves’ orbitopathy in vivo.
In conclusion, the inhibition of GSK-3β blunted the
elevated expression of proinflammatory cytokines in GO
fibroblasts and inhibited activation of proinflammatory tran-
scription factors. The GSK-3β inhibitor CHIR 99021 also
attenuated differentiation of fibroblasts into adipocyte by
regulating both the PPARγ –C/EBPα/β and β-catenin path-
ways. Future studies are needed to establish the response
to GSK-3β inhibitors in vivo and to explore the use of the
inhibitor as a therapeutic agent.
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